Benzinga | Sep 10, 2021 05:00AM EDT

Oppenheimer Upgrades Editas Medicine to Outperform, Raises Price Target to $80

Oppenheimer analyst Jay Olson upgrades Editas Medicine (NASDAQ:EDIT) from Perform to Outperform and raises the price target from $42 to $80.